Eradication of HIV Bonaventura Clotet Hospital Universitàri Germans Trias i Pujol Badalona. Barcelona. Catalonia
|
|
|
- Austen James
- 6 years ago
- Views:
Transcription
1 Eradication of HIV Bonaventura Clotet Hospital Universitàri Germans Trias i Pujol Badalona. Barcelona. Catalonia
2 Dr Bonaventura Clotet Transparency declaration I have served during the past 2 years as a consultant on advisory boards or participated in speakers bureaus or conducted clinical trials with Gilead, ViiV and Merck (MSD)
3 HIV CURE
4 Reservoir: Resting Central & Transitional memory CD4 T cells (CD45RO+) Resting naive CD4T cells Tissue monocyte-derived cells?
5 Kick and Kill Strategy to Eliminate Reservoirs of Latent HIV Post-CROI 2015 Modified Immunoglobulins Het IL15 TLR-7
6 STRATEGIES TO CURE HIV
7 BONE MARROW TRANSPLANTATION
8
9 María Salgado JMPicado Duarte et al Lancet HIV 2(6):e236 e242.
10 Observational project, not a clinical trial, to investigate cases of Allogeneic stem cell transplant in HIV-1-infected individuals THE ICISTEM CONSORTIUM Javier Martinez-Picado (Co-PI, Virologist, AIDS Research Institute IrsiCaixa, Barcelona) Annemarie Wensing (Co-PI, Clinical Virologist, University Medical Center Utrecht) Jose L. Díez Martin & Mi Kwon (Hematologists, Hospital Gregorio Marañón, Madrid) Gero Hütter (Hematologist, Cellex Dresden) Jürgen Kuball (Hematologist, University Medical Center Utrecht) Monique Nijhuis (Virologist, University Medical Center Utrecht) Vanderson Rocha (Hematologist Cord Blood Bank Specialist Oxford University) Asier Sáez-Cirión (Immunologist,Pasteur Institute, Paris) Julian Schulze zur Wiesch (Infectious disease specialist, UMC Hamburg- JMPicado
11 7 patients > 2 years post BM transplantation Off immunosupresor drugs. HIV VL undetectable Mouse VOA negative 11
12 IMMUNOTHERAPY
13 Mascola JR. CROI 2016, Boston MA. #15.
14 ABSTRACT 32LB Passive administration of bnabs (VRC01) prevents HIV-1 transmission in humanized mice, macaques. Transiently reduces plasma viral loads by ~1-3 logs in HIV infected humans
15 Results: Viral rebound HIV-1 RNA (copies/ml) enrollee Weeks post-ati Majority of participants rebounded by week 5 2 participants with delayed rebound at 8, 11 weeks Time to rebound not associated with VRC01 level, age, nadir or entry CD4 ct, time on ART Bar KJ. CROI 2016, Boston, MA. #32LB. A5340
16 Mascola JR. CROI 2016, Boston MA. #15.
17 July 2016
18
19 Future: with 3BNC117 and VRC01 could be a very potent combination
20 Humanized IgG4 mab. Blocks HIV-1 from entering cells. Binds CCR5 with high affinity, potent inhibition. High barrier to resistance. Well tolerated in men, no dose-limiting in animals. Designated FDA fast Track drug candidate. Single IV or weekly SC injections reduced HIV-1 RNA. Phase 2b Study: CCR5, CD4 >350, VL <50 with ART. 350 mg once weekly x 12 w. Those with VL<50 allowed to continue. Lalezari J. ASM Microbe, Boston, MA, #371.
21 Highly potent multifunctional antibodybased molecules against Human Immunodeficiency Virus. Julià Blanco, Jorge Carrillo, Bonaventura Clotet
22 Highly potent multifunctional antibody-based molecules against HIV Recombinant antibodies with enhanced antiviral activity: The ecd4-ig molecule
23 Blocking HIV entry Post-CROI
24 INFECTIVITY INFECTIVITY Highly potent multifunctional antibody-based molecules against HIV Recombinant antibodies: IrsiCaixa molecules 1) Antiviral activity NL43 BaL AC M-0 M-1 M-5 M-7 M-8 M-10 M M-0 M-1 M-5 M-7 M-8 M-10 M M-0 M-1 M-5 M-7 M-8 M-10 M Log [Inhibitor] microg/ml Log [Inhibitor] microg/ml Log [Inhibitor] microg/ml IC50 (ng/ml) NL43 BAL AC10 Description MOLECULE-0 10,820 27,390 >100 1st Generation MOLECULE-1 0,108 0,050 >100 REFERENCE (Farzan s) MOLECULE-5 0,037 0,007 0,375 MOLECULE-7 0,029 0,004 0,189 MOLECULE-8 0,035 0,028 1,327 MOLECULE-10 0,793 2,924 >100 MOLECULE-11 0,110 0,026 1,454 AlbaJuna molecules RATIO MOLECULE-7/ MOLECULE-1 x5 x12 >100
25 MOLECULE-1 MOLECULE-5 MOLECULE-6 MOLECULE-7 MOLECULE-11 Relative ADCC activity (%) Highly potent multifunctional antibody-based molecules against HIV Recombinant antibodies: IrsiCaixa molecules 2) Antibody Dependent Cellular Cytotoxicity (ADCC) ADCC
26 THERAPEUTIC VACCINE
27 Target non-escaped epitopes Deng et al, Nature, 2015
28 HIVACAT T-cell Immunogen design (HTI) Immunogenicity data from >1,000 infected individuals screens for T cell responses to the entire HIV proteome yielded 26 regions identified as beneficial (PR>1) in HIV-1 Gag, Pol, Vif and Nef proteins that were: i) preferentially targeted by individuals with low viral loads, ii) turned out to be more conserved and iii) elicited responses of higher functional avidity and broader cross-reactivity Mothe B et al, PLos One 2012 Mothe B et al, JTM 2012
29 Gag-p24 Gag-p15 Pol-Prot Pol-RT Pol-Int Vif Nef Gag-p17 Gag-p24 Gag-p15 Pol-Prot Pol-RT Pol-Int Vif Nef Gag-p17 Gag-p24 Gag-p15 Pol-Prot Pol-RT Pol-Int Vif Nef IFNg SFC/10 6 splenocytes Gag-p17 Gag-p24 Gag-p15 Pol-Prot Pol-RT Pol-Int Vif Nef IFNg SFC/10 6 splenocytes IFNg SFC/10 6 splenocytes # of HIV suproteins (n=8) with IFNg response # of IFNg responses IFNg SFC/10 6 splenocytes % IFN + CD3 + splenocytes % IFN + CD3 + splenocytes 3 HIVACAT T-cell Immunogen design (HTI) CD CD Gag Gag Pol Pol Vif Vif Nef Nef Mean and SD is shown Mean and SD is shown 2x pdna 2x pdna 1 MVA 3x pdna 3x pdna 1 MVA 2x pdna 2x pdna 1 MVA 3x pdna 3x pdna 1 MVA 6 out of 6 mice cell responses splitted by protein subunits x pdna Gag Pol 1000 Vif 750 Nef DNA + 1 MVA MVA boost increases responses broadly after 3 pdna vaccinations HIV specific induced T cell responses splitted by protein subunits Gag x pdna + 1 MVA Pol Vif Nef pdna: 100µg IM / dose MVA MVA: 10^6pfu IM / dose
30 HIVACAT T-cell Immunogen design (HTI) Interestingly, MVA-HTI vaccine was able to boost responses (both in breadth and magnitude,) in the two groups analyzed, with significantly increased magnitudes of responses in the group that obtained 3 doses of pdna-hti MVA-HIVACAT vaccine Elicits CD8 effector memory response which has been associated with HIV control in Elite Controllers and in the animal model (Picker et al. Nature 2011) Journal of Translational Medicine. Bea Mothe et al 2015
31 Activating latent HIV The Economist, July 17, 2011
32 Activating latent HIV: in vitro Cytokines IL-7 1,2 IL-15 3 IFNa 2b Histone deacetylase (HDAC) inhibitors 4,5 Valproic Acid Vorinostat (SAHA) Romidepsin Panobinostat Anti-alcohol agent Disulfiram 6 Methylation inhibitors 5-aza-dC 7 Immune modulation Anti PD1 NF-kB activators Prostratin, PMA, TNF 4 Akt/HEXIM-1 modulators HMBA 8 Histone Methyltransferase inhibitors (HMTI) 9 Chaetocin, BIX Other Quinolines 10 Combination enhances potency 4,9,11 1 Wang, J Clin Invest 2005; 2 Saleh, Retrovirol 2011; 3 Chomont, 6 th IAS Rome 2011; 4 Contreras, J Biol Chem 2009; 5 Wightman, Immunol Cell Biol 2012; 6 Xing, J Virol 2011; 7 Friedman, J Virol 2011; 8 Contreras PLoS Pathog 2007; 9 Bouchat, AIDS 2012; 10 Xing, J Antimicrob Chemother 2012; 11 Reuse, PLoS One 2009
33
34
35
36
37
38
39 Innate immune detection of microbial nucleic acids #122 #123 #124 #125 TLR: Toll-like Receptor agonists Reactivates the HIV Post-CROI 2015 Gürtler & Bowie Trends Microbiol. 2013
40 The combination of Ad26/MVA vaccination and GS- 986 resulted in a significant 1.74 log reduction in median setpoint viral loads and a 2.5-fold delay in the time to viral rebound following ART discontinuation as compared with sham controls. Moreover, 3 of 9 animals demonstrated virologic control to undetectable levels in the absence of ART. These 3 animals were had high cellular immune magnitude and breadth and negative viral DNA prior to ART discontinuation. These data demonstrate the proof-of-concept that the combination of therapeutic vaccination and innate immune stimulation can impact viral rebound following ART discontinuation.
41 COMBINATION OF STRATEGIES TO ACHIEVE THE CURE OF HIV
42 Multiple strategies for eradication Vaccine (HTI) Infected cell CTL Infected cell destruction HIV-1 infected patient Vaccine (HTI) HIV-1 free individual
43 Multiple strategies for eradication Vaccine (HTI) DC (SIGLEC-1) Delivered HDAC Inhibitors, TLR-7;het-IL15, RIG-I T CTL Infected cell destruction Anti-PD1 boosting? Vaccine (HTI) HIV-1 infected patient HIV-1 free individual
44 Multiple strategies for eradication IgGs AlbaJunaMabs (AJ-Mabs) (IgG+CCR5+CD4+FX) Virus Neutralization by AJ-Mabs Virus inactivation AJ-Mabs Vaccine (HTI) X T New infections protection Infected cell CTL Infected cell destruction Anti-PD1 boosting? Vaccine (HTI) HIV-1 infected patient HIV-1 free individual
45 Multiple strategies for eradication IgGs AlbaJunaMabs (AJ-Mabs) (IgG+CCR5+CD4+FX) Virus Neutralization by AJ-Mabs Virus inactivation AJ-Mabs Vaccine (HTI) X AJ-Mabs T New infections protection Infected cell N K CTL Infected cell destruction Anti-PD1 boosting? Vaccine (HTI) HIV-1 infected patient HIV-1 free individual
46 IgGs AlbaJunaMabs (AJ-Mabs) (IgG+CCR5+CD4+FX) Multiple strategies for eradication Virus Neutralization by AJ-Mabs Virus inactivation AJ-Mabs Therapeutic Vaccine (HTI) HDACs inhibitors delivered through Siglec-1 mechanism; TLR7; Heterodimeric IL-15,RIG-I Anti-PD-1 as CD8 and vaccine boosters? Recombinant proteins (AlbaMab/JunaMab) Microbiome increased diversity?? Vaccine (HTI) DC (SIGLEC-1) Delivered HDAC Inhibitors, TLR-7, hetil-15, RIG-I X AJ-Mabs T New infections protection Infected cell N K CTL Infected cell destruction Anti-PD1 boosting? Vaccine (HTI) HIV-1 infected patient HIV-1 free individual
47 47
48 Special thanks to Javier Martinez-Picado for providing me some of these slides THANK YOU VERY MUCH
Approaching a Cure Daniel R. Kuritzkes, MD
Approaching a Cure Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker is a consultant and/or has received speaking honoraria
State of the ART: HIV Cure where are we now and. where are we going? Jintanat Ananworanich, MD, PhD MHRP
State of the ART: HIV Cure where are we now and ì where are we going? Jintanat Ananworanich, MD, PhD Associate Director for Therapeu1cs Research US Military HIV Research Program (MHRP) Maryland, USA Deputy
MHRP. Outline. Is HIV cure possible? HIV persistence. Cure Strategies. Ethical and social considerations. Short video on patients perspectives on cure
Outline Is HIV cure possible? Ø HIV persistence Cure Strategies Ethical and social considerations Short video on patients perspectives on cure A Case of Cure Off ART Treatment Mechanism Lesson The Berlin
Clinical HIV-1 eradication studies
Clinical HIV-1 eradication studies Mathias Lichterfeld, M. D., Ph. D. Massachusetts General Hospital Harvard Medical School No disclosures HIV-1 persistence despite HAART Blood Tissue HIV RNA (cps/ml)
Inves&gación básica y curación del VIH-1
Inves&gación básica y curación del VIH-1 Javier Mar&nez-Picado 24 th Conference on Retroviruses and Opportunis6c Infec6ons UNIVERSITAT DE VIC Empezamos bien cart: How Early is Early Enough? Sáez-Cirion
Dr Jintanat Ananworanich
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Jintanat Ananworanich US Military HIV Research Program in Bethesda Maryland, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
HIV Cure Update. Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS
HIV Cure Update Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS Financial Disclosures Research grants paid to my institution: Gilead Sciences, Bristol
CROI 2016 Review: Immunology and Vaccines
Frontier AIDS Education and Training Center CROI 2016 Review: Immunology and Vaccines Meena Ramchandani MD MPH Acting Instructor, University of Washington March 2016 This presentation is intended for educational
What is the place of the monoclonal antibodies in the clinic?
What is the place of the monoclonal antibodies in the clinic? Dr Julià Blanco 2018/04/26 DISCLOSURE AlbaJuna Therapeutics, S.L. ANTIBODIES IN HIV INFECTION. ANTIVIRAL (NEUTRALIZING) ACTIVITY env THE BROADLY
Towards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco
Towards an HIV Cure Steven G. Deeks Professor of Medicine University of California, San Francisco Why are we now talking about a cure? Emerging recognition that HAART does not fully restore health and/or
Inves)gación básica y curación del VIH- 1
Inves)gación básica y curación del VIH- 1 Javier Mar)nez- Picado (jmpicado@irsicaixa.es) 23 rd Conference on Retroviruses and Opportunis5c Infec5ons February 22-25, 2016 Boston, Massachuse8s UNIVERSITAT
PROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater
PROSPECTS FOR HIV CURE IN ADULTS FIS 2013 Nov 11 th 2013 John Frater April 29 th 2013; Telegraph online THE COMPONENTS OF A CURE. What is cure? Issues to consider: Post treatment control the benefit of
HIV cure: current status and implications for the future
HIV cure: current status and implications for the future Carolyn Williamson, PhD Head of Medical Virology, Faculty Health Sciences, University of Cape Town CAPRISA Research Associate, Centre of Excellence
Are we targeting the right HIV determinants?
QuickTime et un décompresseur TIFF (non compressé) sont requis pour visionner cette image. AIDS Vaccine 2009 October 22 nd 2009 - Paris Are we targeting the right HIV determinants? Françoise BARRÉ-SINOUSSI
Can HIV be cured? (how about long term Drug free remission?)
Can HIV be cured? (how about long term Drug free remission?) Shirin Heidari International AIDS Society EC Think Tank meeting 27-28 October 2010 Luxemburg HAART can control HIV, cannot eradicate it Life
With over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the
Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several
5/11/2017. HIV Cure Research Questions and a Few Answers
HIV Cure Research Questions and a Few Answers Steven G. Deeks, MD Professor of Medicine University of California San Francisco San Francisco, California FORMATTED: 04/13/17 Financial Relationships With
IAS 2015 Towards an HIV Cure symposium Vancouver Immune recognition following latency reversal
IAS 2015 Towards an HIV Cure symposium Vancouver Immune recognition following latency reversal Marcus Altfeld Professor of Medicine Outline Immune recognition of HIV-1-infected cells Kinetics of antigen
The HIV Cure Agenda. CHIVA Oct Nigel Klein. Institute of Child Health and Great Ormond Street Hospital, London, UK
The HIV Cure Agenda CHIVA Oct 2016 Nigel Klein Institute of Child Health and Great Ormond Street Hospital, London, UK 2 How frequently is HIV cured? The Berlin patient Restriction of HIV entry CD4 is
Preventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt
Preventive and therapeutic HIV vaccines Markus Bickel Infektiologikum Frankfurt No conflicts to declare Disclosures Background FAQ: by patients and colleagues Publication about promising results, especially
23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service,
23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service, SFVAMC March 23, 2016 Boston, MA, February 22-25, 2016 Disclosures
How to best manage HIV patient?
How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to
Sustained HIV- 1 remission following homozygous CCR5 delta- 32 allogeneic haemopoetic stem cell transplantion
Sustained HIV- 1 remission following homozygous CCR5 delta- 32 allogeneic haemopoetic stem cell transplantion R Gupta 1, A Abdulijawad 2, L McCoy 2, D Peppa 3, M Salgado 4, J Martinez- Picado 4, A Wensing
Professor Jonathan Weber
HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust Multidisciplinary Event to mark World AIDS Day 2011 British HIV Association (BHIVA) 2011 HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust
Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir
Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir Giuseppe Pantaleo, M.D. Professor of Medicine Head, Division of Immunology and Allergy Executive Director, Swiss Vaccine
Pediatric HIV Cure Research
Pediatric HIV Cure Research HIV Cure Research Training Curriculum Pediatric HIV Cure Research Presented by: Priyanka Uprety,MSPH, PhD Laboratory of Deborah Persaud, MD Johns Hopkins University July 2016
Deep Sequencing Detects V3 loop Forms Present in Functional X4 Viruses Growing in MT 2 assays
Deep Sequencing Detects V3 loop Forms Present in Functional X4 Viruses Growing in MT 2 assays Christian Pou 1, Rocío Bellido 1, Francisco M. Codoñer 1, Alexander Thielen 3, Cecilia Cabrera 1, Judith Dalmau
HIV-1 envelope glycoproteins isolated from Viremic non-progressors HIV-infected individuals are fully functional and cytophatic
HIV-1 envelope glycoproteins isolated from Viremic non-progressors HIV-infected individuals are fully functional and cytophatic Silvia Marfil 1, Veronique Hebman 2, Sara Marrero-Hernandez 3, Daniel Márquez-Arce
HIV remission: viral suppression in the absence of ART. Sarah Fidler Brian Gazzard Lecture BHIVA 2016
HIV remission: viral suppression in the absence of ART Sarah Fidler Brian Gazzard Lecture BHIVA 2016 Disclosures: My institution receives funding for research from MSD, GSK, ViiV, Gilead Summary of talk
New options for new and old patients. Antonella Castagna
New options for new and old patients Antonella Castagna Disclosures I have received funding for Advisory Boards, Speaker Panels and for preparation of educational materials from the following: Gilead Sciences
PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients
PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients Jay Lalezari, Kush Dhody, Ula Kowalczyk, Kazem Kazempour, Nader Pourhassan, and Paul J. Maddon 1 ASM Microbe 2016
Current Clinical Therapies for HIV Remission. David Margolis MD UNC HIV Cure Center
Current Clinical Therapies for HIV Remission David Margolis MD UNC HIV Cure Center Aiming for sustained remission off ART Cohen J. Science 214 Luzuriaga et al. NEJM 3;8: 786 Effect of vorinostat, hydroxychloroquine
Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
Direct acting anti-virals: the near future
Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should
Treatment of HIV and acute myeloid leukemia by allogeneic CCR5-d32 blood stem cell transplantation. Elena Knops
Treatment of HIV and acute myeloid leukemia by allogeneic CCR5-d32 blood stem cell transplantation Elena Knops Background - the Berlin patient so far the only person presumed to be cured from HIV by hematopoietic
cure research HIV & AIDS
Glossary of terms HIV & AIDS cure research Antiretroviral Therapy (ART) ART involves the use of several (usually a cocktail of three or more) antiretroviral drugs to halt HIV replication. ART drugs may
Working Group#1: Trial Endpoints, Biomarkers & Definitions
Working Group#1: Trial Endpoints, Biomarkers & Definitions Forum HIV Cure Project: Focus on The Regulatory Pathway June 17, 2014 www.hivforum.org Comments from co-chairs john mellors and mike miller www.hivforum.org
A VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
GOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
HIV cure research: current strategies and challenges. current strategies to eliminate latently infected cells 2/10/2015
Viral load // HIV cure research: current strategies and challenges Sharon R Lewin Director, Doherty Institute for Infection and Immunity, The University of Melbourne, Consultant physician, The Alfred,
The HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
How HIV Causes Disease Prof. Bruce D. Walker
How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of
Therapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome
30 1, 1, 2, 3 1. ( ), 201508; 2., 200040; 3., 200032 : ( AIDS) ( HIV) 20 90,,,,,, AIDS, CD4 + T ( CTL), HIV, : ; ; Therapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome
Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure
Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure Deborah Persaud, M.D. Associate Professor Department of Pediatrics Division of Infectious Diseases Johns Hopkins University School of
Perspective HIV Infection: Advances Toward a Cure
Perspective HIV Infection: dvances Toward a Cure chieving cure of HIV infection requires eliminating all replication-competent virus from the reservoir of latently infected cells or completely inhibiting
HIV remission after discontinuing ART: is it achievable?
HIV remission after discontinuing ART: is it achievable? Jintanat Ananworanich, MD, PhD Associate Director for Therapeutics Research US Military HIV Research Program Maryland, USA jananworanich@hivresearch.org
Richard Jefferys Basic Science, Vaccines & Cure Project Director Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting
Richard Jefferys Basic Science, Vaccines & Cure Project Director Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pre-exposure prophylaxis (PrEP)
Identification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Identification and Characterization of CD4 T cells actively transcribing
HIV Anti-HIV Neutralizing Antibodies
,**/ The Japanese Society for AIDS Research The Journal of AIDS Research : HIV HIV Anti-HIV Neutralizing Antibodies * Junji SHIBATA and Shuzo MATSUSHITA * Division of Clinical Retrovirology and Infectious
Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
Supporting Information
Supporting Information Sui et al..7/pnas.997 Pre-CLP CM9 LA9 SL Tat# Pol Vif % Tetramer + CD + CD + Vac+IL- +IL- Vac Fig. S. Frequencies of six different CD + CD + Mamu-A*-tetramer + cells were measured
NIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2013 September 01.
NIH Public Access Author Manuscript Published in final edited form as: J Acquir Immune Defic Syndr. 2012 September 1; 61(1): 19 22. doi:10.1097/qai.0b013e318264460f. Evaluation of HIV-1 Ambiguous Nucleotide
Hot Topics in HIV. Barcelona 2018
Hot Topics in HIV. Barcelona 2018 Paving the way to an AIDS-free World. Mario Stevenson, PhD. Department of Medicine. Reproductive Cycle of HIV and Sites of Action of Major Classes of Antiretroviral Medications
Can we eradicate HIV?
Can we eradicate HIV? New therapeutic strategies towards a cure Laurence COLIN Laboratory of Molecular Virology University of Brussels Belgium The success story of HAART encountered solid barriers to virus
HIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks
HIV Antibody Characterization for Reservoir and Eradication Studies Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks Blood Systems Research Institute University of California San Francisco, CA
The potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies
The potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies Stephen Mason Director, Discovery Virology Bristol-Myers Squibb Community Cure Workshop 2015 Sunday, Feb 22, 2015 Seattle,
VACUNAS FELIPE GARCÍA HOSPITAL CLINIC. BARCELONA RESUMEN CROI 2016
VACUNAS FELIPE GARCÍA HOSPITAL CLINIC. BARCELONA RESUMEN CROI 2016 bnabs Abstract 32LB and 311: infusión VRC01 uso terapéulco y STI Abstract 90: VRC01 uso prevenlvo Abstract 303: bnabs en PHI VACUNAS PREVENTIVAS
Are Immune Modulators Really Needed to Cure HBV infection?
Are Immune Modulators Really Needed to Cure HBV infection? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto,
Broadly Neutralizing Antibodies for HIV Eradication
DOI 10.1007/s11904-016-0299-7 HIV PATHOGENESIS AND TREATMENT (AL LANDAY, SECTION EDITOR) Broadly Neutralizing Antibodies for HIV Eradication Kathryn E. Stephenson 1,2 & Dan H. Barouch 1,2 # The Author(s)
The Third D: Long Term Solutions to End the Epidemic. Mitchell Warren Executive Director, AVAC 12 February 2014
The Third D: Long Term Solutions to End the Epidemic Mitchell Warren Executive Director, AVAC 12 February 2014 Key clinical trial milestones: HIV vaccine research First HIV vaccine trial opens Phase
Should There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Should There be Further Efficacy
NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections
NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections Amy Chung Dr. Ivan Stratov Prof. Stephen Kent ADCC process consists of Target cell QuickTime and a TIFF (Uncompressed) FcγR decompressor
Professor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
SUPPLEMENTARY INFORMATION
` SUPPLEMENTAL FIGURES doi:10.1038/nature10003 Supplemental Figure 1: RhCMV/SIV vectors establish and indefinitely maintain high frequency SIV-specific T cell responses in diverse tissues: The figure shows
Invited Review CROI 2018: Advances in Basic Science Understanding of HIV
Invited Review CROI 2018: Advances in Basic Science Understanding of HIV Mario Stevenson, PhD The conference on Retroviruses and Opportunistic Infections represents the most important venue for the dissemination
Why are validated immunogenicity assays important for HIV vaccine development?
Why are validated immunogenicity assays important for HIV vaccine development? There is a need to compare immunogenicity of products in the pipeline, when similar or different in class when developed by
Engineered Immune-Mobilising Monoclonal T Cell Receptors for HIV Cure
Engineered Immune-Mobilising Monoclonal T Cell Receptors for HIV Cure Zoë Wallace Nuffield Dept. of Medicine University of Oxford 23 rd Annual Conference of the British HIV Association The HIV Reservoir
DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04)
DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04) Rashmi Jalah Human Retrovirus Pathogenesis Section, Vaccine Branch, CCR, National Cancer Institute
Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement
Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement Fabien Zoulim Service d hépatologie, Hospices Civils de Lyon INSERM U1052, Cancer
Clinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX
Clinical Development of ABX464, drug candidate for HIV Functional Cure Jean-Marc Steens, MD Chief Medical Officer ABIVAX 1 DECLARATION OF CONFLICT OF INTEREST GSK ABIVAX 2 ABX464: Mechanism of Action ABX464
HCV Vaccine where do we stand? U. Spengler University of Bonn
HCV Vaccine where do we stand? U. Spengler University of Bonn THE IDEAL GOAL: The vaccine should induce sterilizing immunity A MORE REALISTIC GOAL: Prevention of chronic persistent infection Feinstone
A Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
Supporting Information
Supporting Information Horwitz et al. 73/pnas.35295 A Copies ml - C 3NC7 7 697 698 7 7 73 76-2 2 Days Gp2 residue G458D G459D T278A 7/36 N28 K D 28 459 A28T ID# 697 ID# 698 ID# 7 ID# 7 ID# 73 ID# 76 ID#
Therapeutic DNA Vaccine Induces Broad T Cell Responses in the Gut and Sustained Protection from Viral Rebound and AIDS in SIV-Infected Rhesus Macaques
Therapeutic DNA Vaccine Induces Broad T Cell Responses in the Gut and Sustained Protection from Viral Rebound and AIDS in SIV-Infected Rhesus Macaques Deborah Heydenburg Fuller 1,2,3 * a, Premeela Rajakumar
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
Roger Shapiro, MD, MPH Harvard TH Chan School of Public Health Botswana-Harvard Partnership May 2018
A Clinical Trial to Evaluate the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana Roger Shapiro, MD, MPH
Functional cure of HIV: the scale of the challenge. *, David S. Khoury 1
AnaLysIs Functional cure of HIV: the scale of the challenge Miles P. Davenport 1 *, David S. Khoury 1, Deborah Cromer 1, Sharon R. Lewin 2,3, Anthony D. Kelleher 1 and Stephen J. Kent 2,3,4,5 Abstract
HBV Novel Therapies Maria Buti MD, PhD
HBV Novel Therapies Maria Buti MD, PhD Liver Unit, Internal Medicine Department Vall d Hebron Hospital CONFLICT OF INTEREST I have financial relationships to disclose within the past 12 months relevant
Early Antiretroviral Therapy
Early Antiretroviral Therapy HIV Cure Research Training Curriculum HIV and Cure Early ART Presented by: Jintanat Ananworanich, MD, PhD June 2016 The HIV CURE research training curriculum is a collaborative
IMMUNOLOGICAL MEMORY. CD4 T Follicular Helper Cells. Memory CD8 T Cell Differentiation
IMMUNOLOGICAL MEMORY CD4 T Follicular Helper Cells Memory CD8 T Cell Differentiation CD4 T Cell Differentiation Bcl-6 T-bet GATA-3 ROR t Foxp3 CD4 T follicular helper (Tfh) cells FUNCTION Provide essential
DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED
DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps
CROI 2016: Top Ten for Clinicians
Hynes Convention Center. Boston, MA; US. Feb 22-25, 2016 CROI 2016: Top Ten for Clinicians Josep M Llibre Hospital Universitari Germans Trias i Pujol Fundació Lluita contra la SIDA Badalona, Barcelona
Lynn Morris. "Plan B"- bnabs for HIV prevention
"Plan B"- bnabs for HIV prevention Lynn Morris National Institute for Communicable Diseases, a division of the National Health Laboratory Service (NHLS) of South Africa, University of the Witwatersrand,
HIV Remission: Compound screening and optimization. Michael D. Miller
HIV Remission: Compound screening and optimization Michael D. Miller Can we drive HIV into remission in large numbers of patients? "George Bernard Shaw, speaking as an Irishman, summed up an approach to
HIV cure strategies: interventions, endpoints and ethics
HIV cure strategies: interventions, endpoints and ethics Professor Sharon R Lewin, FRACP, PhD, FAHMS Fourth Joint Conference of BHIVA with BASSH, April 17-20, Edinburgh International Conference Centre,
The Impact of Immunoglobulin in Acute HIV Infection on the HIV Reservoir: A Pilot Randomized Controlled Trial
The Impact of Immunoglobulin in Acute HIV Infection on the HIV Reservoir: A Pilot Randomized Controlled Trial Olubanke Davies Guy s & St Thomas NHS Foundation Trust BACKGROUND Immediate ART during acute
Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells
Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells Sharon A. Riddler, MD, MPH University of Pittsburgh May 2008 Slide 1 HIV and DC Vaccines During
IAS 2013 Towards an HIV Cure Symposium
Entinostat is a histone deacetylase (HDAC) inhibitor selective for class 1 HDACs and activates HIV production from latently infected primary T-cells Fiona Wightman Monash University, Melbourne, Australia
Safety and viral load changes in HIV-1 infected subjects treated with autologous dendritic cell immune therapy following ART discontinuation
Safety and viral load changes in HIV-1 infected subjects treated with autologous dendritic cell immune therapy following ART discontinuation (CTN #239) Jean-Pierre Routy M.D. McGill University Paris 21
Update on HIV Cure Research
Update on HIV Cure Research Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland FORMATTED: /7/5 New Orleans, Louisiana: December 5-7,
Hacia la Curación del VIH
Jornadas 2012 Actualización en Atención Farmacéutica al Paciente Con Patologías Víricas Hacia la Curación del VIH Santiago Moreno Servicio de Enfermedades Infecciosas Hospital Ramón y Cajal Madrid HIV
Pathogenesis Update Robert F. Siliciano, MD, PhD
Pathogenesis Update Robert F. Siliciano, MD, PhD Professor of Medicine and Molecular Biology and Genetics Johns Hopkins University School of Medicine Investigator, Howard Hughes Medical Institute HIV-1
HIV Pathogenesis and Natural History. Peter W. Hunt, MD Associate Professor of Medicine University of California San Francisco
HIV Pathogenesis and Natural History Peter W. Hunt, MD Associate Professor of Medicine University of California San Francisco Learning Objectives Describe key features of HIV pathogenesis and natural history
T Lymphocyte Activation and Costimulation. FOCiS. Lecture outline
1 T Lymphocyte Activation and Costimulation Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline T cell activation Costimulation, the B7:CD28 family Inhibitory receptors of T cells Targeting costimulators for
5/19/2018. Disclosures. Lets start with definitions The cure continuum. Efforts and advances for the Cure
Efforts and advances for the Cure Pablo Tebas, MD Disclosures Consulting for Merck, Viiv and Gilead Write for uptodate 2 Lets start with definitions The cure continuum Long acting ART (Control of viremia
Fayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES
1 of 7 I. Viral Origin. A. Retrovirus - animal lentiviruses. HIV - BASIC PROPERTIES 1. HIV is a member of the Retrovirus family and more specifically it is a member of the Lentivirus genus of this family.
Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication
Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication Oscar Blanch-Lombarte Rome, 7-9 June, 2017 European
Module R: Recording the HIV Reservoir
Module R: Recording the HIV Reservoir Satish K. Pillai, Ph.D. MODULE LEADER Satish Pillai amfar Institute for HIV Cure Research Module R Team Michael Busch Timothy Henrich Sheila Keating Sulggi Lee Henry
Advances in HIV science and treatment. Report on the global AIDS epidemic,
HIV biomolecular advances and treatment updates David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia UNAIDS: global l HIV infections
Bispecific Fusion Antibodies. Exhibit 100% Breadth and Picomolar Potency. Craig Pace, PhD
The Aaron Diamond AIDS Research Center Affiliate of The Rockefeller University Bispecific Fusion Antibodies PG9 Ibalizumab & VRC Ibalizumab Exhibit % Breadth and Picomolar Potency Craig Pace, PhD AIDS